DE602007010312D1 - Purinonderivate als hm74a-agonisten - Google Patents

Purinonderivate als hm74a-agonisten

Info

Publication number
DE602007010312D1
DE602007010312D1 DE602007010312T DE602007010312T DE602007010312D1 DE 602007010312 D1 DE602007010312 D1 DE 602007010312D1 DE 602007010312 T DE602007010312 T DE 602007010312T DE 602007010312 T DE602007010312 T DE 602007010312T DE 602007010312 D1 DE602007010312 D1 DE 602007010312D1
Authority
DE
Germany
Prior art keywords
hm74a agonists
purinone derivatives
purinone
derivatives
hm74a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007010312T
Other languages
English (en)
Inventor
Brian Metcalf
Ke Zhang
Changsheng Zheng
Chu-Biao Xue
Ganfeng Cao
Anlai Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of DE602007010312D1 publication Critical patent/DE602007010312D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
DE602007010312T 2006-06-23 2007-06-22 Purinonderivate als hm74a-agonisten Active DE602007010312D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81593506P 2006-06-23 2006-06-23
US92292407P 2007-04-11 2007-04-11
PCT/US2007/071895 WO2007150026A2 (en) 2006-06-23 2007-06-22 Purinone derivatives as hm74a agonists

Publications (1)

Publication Number Publication Date
DE602007010312D1 true DE602007010312D1 (de) 2010-12-16

Family

ID=38705054

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007010312T Active DE602007010312D1 (de) 2006-06-23 2007-06-22 Purinonderivate als hm74a-agonisten

Country Status (14)

Country Link
US (3) US7462624B2 (de)
EP (1) EP2049544B9 (de)
JP (2) JP5274455B2 (de)
KR (1) KR20090025262A (de)
AR (1) AR061626A1 (de)
AT (1) ATE486874T1 (de)
AU (1) AU2007260852B2 (de)
CA (1) CA2656002A1 (de)
DE (1) DE602007010312D1 (de)
IL (1) IL195896A0 (de)
MX (1) MX2009000169A (de)
NO (1) NO20085099L (de)
TW (1) TWI423978B (de)
WO (1) WO2007150026A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
DE602007010312D1 (de) * 2006-06-23 2010-12-16 Incyte Corp Purinonderivate als hm74a-agonisten
US7511050B2 (en) * 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
US20120316176A1 (en) * 2009-12-22 2012-12-13 Deen Tulshian DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b] PURIN-4(5H)-ONE and METHODS OF USE THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
JP2015131783A (ja) * 2014-01-14 2015-07-23 株式会社日本ファインケム アリール−１，２，４−トリアゾール誘導体の製造方法
JP6678685B2 (ja) * 2015-01-30 2020-04-08 上海珊▲頓▼医▲薬▼科技有限公司Ｓｈａｎｔｏｎ Ｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 尿酸性または痛風性疾患の予防または治療
WO2018038340A2 (en) 2016-08-24 2018-03-01 Samsung Electronics Co., Ltd. Electronic device including light-emitting elements and method of operating electronic device
US20210347778A1 (en) * 2018-08-30 2021-11-11 Tera Stone Co., Ltd Hydrazinopurine compound and triazolopurine compound for inhibiting xanthine oxidase

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404380A (en) * 1977-02-14 1983-09-13 Mead Johnson & Company Triazolopyrimidines
US5132424A (en) 1988-07-21 1992-07-21 The Upjohn Company Pyrazolo-pyrrolo-pyrimidine-diones
DE69029303T2 (de) * 1989-09-14 1997-05-28 Kyowa Hakko Kogyo Kk 5-Triazolo(3,4-i)purinderivate
WO1998056820A1 (en) 1997-06-12 1998-12-17 Smithkline Beecham Corporation Hm74a receptor
EP1092435B1 (de) * 1998-07-02 2007-04-04 Kyowa Hakko Kogyo Co., Ltd. Antidiabetische medikamente
WO2001047931A1 (fr) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Derives de purine fondue
SI1294358T1 (en) 2000-06-28 2004-12-31 Smithkline Beecham Plc Wet milling process
KR20040011439A (ko) 2000-12-01 2004-02-05 바이오겐, 인코포레이티드 Ａ1 아데노신 수용체 길항제로서 축합된 퓨린 유도체
EP1377834A2 (de) 2001-04-11 2004-01-07 Glaxo Group Limited Medikamente die modulatoren von hm74 und/oder hm74a activität sind
UA80258C2 (en) 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7465548B2 (en) 2003-02-17 2008-12-16 Bayer Healthcare Ag Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a
CA2556073C (en) * 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
US20060078916A1 (en) 2004-08-27 2006-04-13 Luc Aguilar HM74 and HM74a in cuboidal endothelial cells as associated with inflammation
KR20070070231A (ko) 2004-10-22 2007-07-03 스미스클라인 비참 코포레이션 Ｈｍ７４ａ 수용체 활성을 가지는 크산틴 유도체
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
KR20080034993A (ko) 2005-08-10 2008-04-22 스미스클라인 비참 코포레이션 선택적 ｈｍ７４ａ 작동제로서의 크산틴 유도체
GB0516462D0 (en) 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
US7511050B2 (en) 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
DE602007010312D1 (de) * 2006-06-23 2010-12-16 Incyte Corp Purinonderivate als hm74a-agonisten

Also Published As

Publication number Publication date
AU2007260852A1 (en) 2007-12-27
EP2049544B9 (de) 2011-07-20
JP2013151513A (ja) 2013-08-08
EP2049544A2 (de) 2009-04-22
MX2009000169A (es) 2009-01-26
US20090076269A1 (en) 2009-03-19
CA2656002A1 (en) 2007-12-27
JP5274455B2 (ja) 2013-08-28
US7462624B2 (en) 2008-12-09
NO20085099L (no) 2009-02-16
TWI423978B (zh) 2014-01-21
IL195896A0 (en) 2009-09-01
AR061626A1 (es) 2008-09-10
WO2007150026A2 (en) 2007-12-27
ATE486874T1 (de) 2010-11-15
US20090088446A1 (en) 2009-04-02
EP2049544B1 (de) 2010-11-03
JP2009541356A (ja) 2009-11-26
US7863285B2 (en) 2011-01-04
AU2007260852B2 (en) 2013-01-10
US7902205B2 (en) 2011-03-08
US20080045555A1 (en) 2008-02-21
TW200811181A (en) 2008-03-01
KR20090025262A (ko) 2009-03-10
WO2007150026A3 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
ATE486874T1 (de) Purinonderivate als hm74a-agonisten
ATE487719T1 (de) Xanthinderivate als selektive hm74a-agonisten
IL195904A0 (en) Purinone derivatives as hm74a agonists
ATE475662T1 (de) Dihydropyrazolopyrimidinonderivate
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
ATE512135T1 (de) Spiroindolinonderivate
ATE414085T1 (de) Purinderivate als a2a-rezeptoragonisten
DK2035394T3 (da) 2-pyrazincarboxamidderivater
NL1031741A1 (nl) Purinederivaten.
NO20085127L (no) Leptomycinderivater
DK2277509T5 (da) DPP-IV-inhibitorformuleringer
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
BRPI0807911A2 (pt) Agonistas de alfa2c adrenorreceptor
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
FR2902426B1 (fr) Derives de cinnamoyl-piperazine
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
CR10520A (es) Derivados de purina como agonistas de a2a
DK1971588T3 (da) Tiglien-3-onderivater
DE602006007832D1 (de) Benzotriazolderivate als cannabinoidrezeptorantagonisten
ATE541837T1 (de) Oxaphenanthren-derivate